Therapeutic Drug Monitoring of Protein Kinase Inhibitors in Breast Cancer Patients
Jaroslava Roušarová, Martin Šíma, Ondřej Slanař
zveřejněno: 20. 12. 2021
Protein kinase inhibitors (PKIs) represent up-to-date therapeutic approach in breast cancer treatment. Although cancer is a rapidly progressive disease, many substances, including PKIs, are usually used at fixed doses without regard to each patient’s individuality. Therapeutic drug monitoring (TDM) is a tool that allows individualization of therapy based on drug plasma levels. For TDM conduct, exposure-response relationships of drug substances are required. The pharmacokinetic data and exposure-response evidence supporting the use of TDM for 6 PKIs used in breast cancer treatment, one of the most common female tumour diseases, are discussed in this review.
Klíčová slova: Abemaciclib; Everolimus; Lapatinib; Neratinib; Palbociclib; Ribociclib
Therapeutic Drug Monitoring of Protein Kinase Inhibitors in Breast Cancer Patients is licensed under a Creative Commons Attribution 4.0 International License.